arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

download Export Data

Relay Therapeutics, Inc.

RLAY

$18.02 ▼ -1.35 (-6.97%) at close

8 Visible periods

26 Metrics

Peer-ranked Benchmarks

Price Chart

Health

Poor

Bearish

auto_awesome

Analytical Summary

Relay Therapeutics, Inc. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $3.1B

Dividend Yield —

Revenue Growth 53.4% ↗

Op. Margin None

ROIC -42.2% ↘

FCF / Share $-1.37 ↗

Trailing P/E —

Price / Book 5.5x

FCF Yield —

Debt / Equity —

info Valuation on last close. End-of-day price, Sep 23, 2026.

8-Year Financial Trajectory

Annual

Metric Value Trend Year over Year Percentile

Revenue Total top-line sales

$15.36M

↑ +53.4% —

Net Income Profit after all expenses

$-276.48M

↑ +18.1% —

FCF / Share Free cash flow per share

$-1.37

↑ +21.8% —

trending_up

Bullish Indicators

No bullish signals detected.

warning

Bearish Risks

Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns ↓

Cash Quality ↑

Financial view

Statement lens

Choose the reporting cadence, isolate a period range, or search directly for a metric.

Cadence

Annual Quarterly

Range

→

📈 Is growth accelerating? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue Growth YoY (%)	53.4% Excellent ↓ Excellent Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+568%)	-60.8% Weak ↓ Weak Declining Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-860%)	1749.8% Excellent ↑ Excellent Improving Year-over-year change in total revenue Optimal: > 10% vs Sector: Above avg (+21773%)	-54.4% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-780%)	-96.3% Weak Weak Year-over-year change in total revenue Optimal: > 10% vs Sector: Below avg (-1304%)	—	—	—
EPS Growth YoY (%)	31.8% Excellent ↑ Excellent Improving Year-over-year change in earnings per share Optimal: > 10%	15.4% Good ↑ Good Improving Year-over-year change in earnings per share Optimal: > 10%	-7.7% Weak Weak Year-over-year change in earnings per share Optimal: > 10%	32.2% Excellent Excellent Year-over-year change in earnings per share Optimal: > 10%	—	—	—	—
Net Income Growth YoY (%)	18.1% Good ↑ Good Improving Year-over-year change in net income	1.2% Caution ↑ Caution Improving Year-over-year change in net income	-17.7% Weak ↑ Weak Improving Year-over-year change in net income	20.2% Good ↑ Good Improving Year-over-year change in net income	-594.3% Weak Weak Year-over-year change in net income	30.4% Excellent Excellent Year-over-year change in net income	—	—
FCF Growth YoY (%)	21.8% Good ↑ Good Improving Year-over-year change in free cash flow	29.2% Excellent ↑ Excellent Improving Year-over-year change in free cash flow	-16.9% Weak Weak Year-over-year change in free cash flow	-159.7% Weak Weak Year-over-year change in free cash flow	—	—	—	—
Revenue CAGR 3Y (%)	123.2% Excellent ↑ Excellent Improving Compound annual revenue growth over 3 years	48.9% Excellent Excellent Compound annual revenue growth over 3 years	-32.4% Weak Weak Compound annual revenue growth over 3 years	—	—	—	—	—
Revenue CAGR 5Y (%)	-28.6% Weak Weak Compound annual revenue growth over 5 years	—	—	—	—	—	—	—

💰 Are margins durable? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Operating Margin (%) (%)	—	—	—	—	—	-67.5% Weak Weak Operating income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-550%)	—	—
Profit Margin (%) (%)	—	—	—	—	—	-63.4% Weak Weak Net income as a percentage of revenue Optimal: > 15% vs Sector: Below avg (-628%)	—	—
FCF Margin (%) (%)	—	—	—	—	—	-126.3% Weak Weak Free cash flow as a percentage of revenue Optimal: > 10%	—	—
FCF / Net Income (x)	0.85x Caution → Caution Stable Free cash flow relative to reported net income Optimal: > 1x	0.74x Caution ↑ Caution Improving Free cash flow relative to reported net income Optimal: > 1x	0.89x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.82x Caution ↓ Caution Declining Free cash flow relative to reported net income Optimal: > 1x	0.21x Weak ↓ Weak Declining Free cash flow relative to reported net income Optimal: > 1x	1.99x Excellent Excellent Free cash flow relative to reported net income Optimal: > 1x	0.98x Caution Caution Free cash flow relative to reported net income Optimal: > 1x	—

🎯 Is capital allocation efficient? 3 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Return on Invested Capital (%)	-42.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-37.8% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-39.2% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-24.9% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-32.1% Weak ↓ Weak Declining Return earned on debt + equity capital invested Optimal: > 10%	-5.8% Weak Weak Return earned on debt + equity capital invested Optimal: > 10%	36.8% Excellent Excellent Return earned on debt + equity capital invested Optimal: > 10%	—
Return on Capital (%) (%)	-48.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-42.7% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-44.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-27.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-36.2% Weak ↓ Weak Declining Operating profit relative to total assets Optimal: > 10%	-7.0% Weak Weak Operating profit relative to total assets Optimal: > 10%	-21.4% Weak Weak Operating profit relative to total assets Optimal: > 10%	—
Return on Common Equity (%) (%)	-48.8% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-425%)	-43.4% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-389%)	-45.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-403%)	-30.6% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-304%)	-40.5% Weak ↓ Weak Declining Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-370%)	-6.9% Weak Weak Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Below avg (-146%)	41.7% Excellent Excellent Profit generated per dollar of shareholder equity Optimal: > 15% vs Sector: Above avg (+178%)	—

⚖️ Is the balance sheet risky? 1 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Net Debt (USD)	$-84.02M	$-124.29M	$-143.74M	$-151.79M	$-280.12M	$-447.65M	$-41.95M	—

📊 What does each share earn? 6 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Revenue per Share (USD)	$0.09	$0.07	$0.21	$0.01	$0.03	—	—	—
Basic EPS, GAAP (USD)	$-1.61	$-2.36	$-2.79	$-2.59	$-3.82	—	—	—
Free Cash Flow per Share (USD)	$-1.37	$-1.76	$-2.48	$-2.13	$-0.82	—	—	—
Book Value per Share (USD)	$3.26	$4.64	$5.90	$7.85	$8.30	$8.49	$-44.69	—
Tangible Book Value per Share (USD)	$3.26	$4.64	$5.90	$7.85	$8.30	$8.49	$-44.69	—
Basic Weighted Avg Shares (shares)	171.59M	142.87M	122.58M	112.23M	95.14M	—	—	—

🏦 How resilient is the balance sheet? 2 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Working Capital (USD)	$552.70M	$758.48M	$739.83M	$955.80M	$951.92M	$756.47M	$348.55M	—
Total Equity (USD)	$567.06M	$777.79M	$752.00M	$950.22M	$897.81M	$763.29M	$-180.44M	$-110.93M

📋 What is driving earnings? 4 metrics

Metric	FY 2025 Dec 31, 2025 10-K ↗	FY 2024 Dec 31, 2024 10-K ↗	FY 2023 Dec 31, 2023 10-K ↗	FY 2022 Dec 31, 2022 10-K ↗	FY 2021 Dec 31, 2021 10-K ↗	FY 2020 Dec 31, 2020 10-K ↗	FY 2019 Dec 31, 2019 10-K ↗	FY 2018 Dec 31, 2018 10-K ↗
Sales/Revenue/Turnover (USD)	$15.36M	$10.01M	$25.55M	$1.38M	$3.03M	$82.65M	—	—
Depreciation Expense (USD)	$3.56M	$5.46M	$5.27M	$4.13M	$3.92M	$3.55M	$2.85M	—
Net Income, GAAP (USD)	$-276.48M	$-337.71M	$-341.97M	$-290.51M	$-363.87M	$-52.41M	$-75.31M	—
Operating Cash Flow (USD)	$-235.46M	$-249.11M	$-300.32M	$-229.49M	$-74.41M	$-102.49M	$-66.13M	—

⌨️ Keyboard Shortcuts

/ Search

Esc Clear

A Annual

Q Quarterly

1-7 Jump to category

R Reset

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 8 years · 31 quarters

Relay Therapeutics, Inc.

Analytical Summary

8-Year Financial Trajectory

Bullish Indicators

Bearish Risks

Health Breakdown

Statement lens

Benchmark Lens

Signals

Percentile Rankings

Peer Comparison

Compare RLAY with peers